Latest Teva Pharmaceuticals News & Updates

See the latest news and media coverage for Teva. We track all announcements, press releases, and industry mentions in real time, all in one place.

Teva Pharmaceuticals (Teva)

Biopharmaceutical and generics company

tevapharm.com

Headquarters: Tel-Aviv, Israel
Company type: Public company
Number of employees: 30,000+
Industry: Pharmaceuticals

Last updated Today

Latest news about Teva Pharmaceuticals (Teva)

In short: Teva expanded its biosimilar and innovative portfolios through strategic acquisitions and licensing deals while reporting strong growth.

Company announcements

July 9 Teva

Teva and Polpharma Biologics announce Ocrevus biosimilar deal

Polpharma retains development and manufacturing; Teva will commercialize the biosimilar globally after regulatory approval.

July 7 Teva

Teva advances anti-IL-15 antibody to Phase 2b for vitiligo

Encouraging Phase 1b results showed improved skin pigmentation; drug designed for convenient quarterly subcutaneous dosing.

June 18 Teva

Teva submits NDA for ecopipam for pediatric Tourette syndrome

The NDA is supported by positive Phase 3 data and could be the first FDA-approved treatment for this condition in over a decade.

June 10 Teva

Teva closes acquisition of Emalex Biosciences, strengthening neuroscience pipeline

The $700M deal adds ecopipam, a late-stage asset for pediatric Tourette syndrome, to Teva's pipeline.

Media coverage

July 13 Law360

Revives Teva Suit Over Eli Lilly Generic Drug Block - Law360

The Seventh Circuit on Monday revived a breach-of-contract lawsuit against Eli Lilly, ruling that an earlier legal settlement under which Eli Lilly agreed not to...

July 10 Law360

Won't Rethink Corcept Patent Loss In Teva Case - Law360 UK

Corcept Therapeutics Inc. lost its bid Friday to have the full Federal Circuit look at a panel's refusal to revive its suit accusing Teva Pharmaceuticals...

July 9 The Pharma Letter

Teva boosts biosimilars pipeline with Ocrevus licensing deal

Israeli drugmaker Teva Pharmaceutical Industries has expanded its biosimilars pipeline through a global licensing agreement with Polpharma Biologics for a proposed copy of Roche's multiple...

July 9 AFP

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale," said Anjan Selz, Chief Executive Officer of Polpharma...

Never miss news about Teva

Track Teva and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Teva competitors & trending companies

Browse news for competitors to Teva and other trending companies.